Ilaris approval could be doubtful for gout and juvenile rheumatoid arthritis

Anonymous

Guest
UPDATE 2-US FDA staff-Novartis gout drug data 'complicated'

Fri Jun 17, 2011 10:41am EDT

* Drug reduces pain but infection risks seen

* Novartis shares flat (Adds FDA staff, Novartis, analyst comments)

By Lisa Richwine

WASHINGTON, June 17 (Reuters) - A Novartis AG (NOVN.VX) (NVS.N) medicine reduced pain from gout but also appeared to raise the chances of serious infections and other problems, U.S. drug reviewers said.

Food and Drug Administration staff, in documents released on Friday, said determining whether the benefits of Ilaris outweighed risks was "complicated" in part because the product has extended effects in the body that are not typical of an acute treatment. The impact of just a single injection may be "protracted," FDA reviewer Sarah Yim wrote in a memo to an advisory panel that meets Tuesday.

The panel of outside experts will decide whether to recommend approval of Ilaris, another crappy novartis overpriced drug, for gout and juvenile rheumatoid arthritis,
which is now sold for treating a rare inflammatory disorder.

(edited for proper content)


and you wonder why execs are dumping the stock & posting love threads ???

Can you say Enron the sequel ?
 






UPDATE 2-US FDA staff-Novartis gout drug data 'complicated'

Fri Jun 17, 2011 10:41am EDT

* Drug reduces pain but infection risks seen

* Novartis shares flat (Adds FDA staff, Novartis, analyst comments)

By Lisa Richwine

WASHINGTON, June 17 (Reuters) - A Novartis AG (NOVN.VX) (NVS.N) medicine reduced pain from gout but also appeared to raise the chances of serious infections and other problems, U.S. drug reviewers said.

Food and Drug Administration staff, in documents released on Friday, said determining whether the benefits of Ilaris outweighed risks was "complicated" in part because the product has extended effects in the body that are not typical of an acute treatment. The impact of just a single injection may be "protracted," FDA reviewer Sarah Yim wrote in a memo to an advisory panel that meets Tuesday.

The panel of outside experts will decide whether to recommend approval of Ilaris, another crappy novartis overpriced drug, for gout and juvenile rheumatoid arthritis,
which is now sold for treating a rare inflammatory disorder.

(edited for proper content)


and you wonder why execs are dumping the stock & posting love threads ???

Can you say Enron the sequel ?


Come on give me a break!

What was the P value and was there more than 10 patients? Was there a true control??

Yah but this is all wall street bull tactics trying to tear us down. Ilaris is awesome, do the research for yourself and see how cool it is. Elidel to was a breakthrough and look how media hurt this drug. Bad, bad media as for the wall street folks poo poo on you and let us do what we know best. ILaris can change peoples lives, make them better and who c areas about price when it brings a smile to someones face :) Raise your arms and scream "We are not gonna take this anymore"! stand up for your company and enjoy the free lunches.
 






Dr. here to say,
I wouldn't prescribe this piece of garbage to one of the thousands of Novartis drug tested & tortured dead animals Vasella has buried in his hunting lodge.
 


















Come on give me a break!

What was the P value and was there more than 10 patients? Was there a true control??

Yah but this is all wall street bull tactics trying to tear us down. Ilaris is awesome, do the research for yourself and see how cool it is. Elidel to was a breakthrough and look how media hurt this drug. Bad, bad media as for the wall street folks poo poo on you and let us do what we know best. ILaris can change peoples lives, make them better and who c areas about price when it brings a smile to someones face :) Raise your arms and scream "We are not gonna take this anymore"! stand up for your company and enjoy the free lunches.

I've been drinking koolaid for years and years, yet people tell me drinking koolaid is not a good thing to do. What's wrong with koolaid?